Disclosure: J.H. Terheyden, Heidelberg Engineering (F), Optos (F), Carl Zeiss Meditec (F), CenterVue (F); L. Mekschrat, None; R.A.D. Ost, Heidelberg Engineering (F), Optos (F), Carl Zeiss Meditec (F), CenterVue (F); G. Bildik, Heidelberg Engineering (F), Optos (F), Carl Zeiss Meditec (F), CenterVue (F); M. Berger, None; M.W.M. Wintergerst, DigiSight Technologies (R), D-EYE Srl (F), Heine Optotechnik GmbH (F, C, R), Eyenuk, Inc. (F), ASKIN & CO GmbH (R), Berlin-Chemie AG (F, R), Heidelberg Engineering (F), Optos (F), Carl Zeiss Meditec (F), CenterVue (F); F.G. Holz, Acucela (C, F, R), Allergan (F, R), Appelis (C, R), Bayer (C, F, R), Boehringer Ingelheim (C), Bioeq/Formycon (F, C), CenterVue (F), Ellex (R), Roche/Genentech (C, F, R), Geuder (C), Grayburg Vision (C, R), Heidelberg Engineering (C, F, R), Kanghong (C, F), Lin BioScience (C, R), NightstaRx (F), Novartis (C, F, R), Optos (F), Pixium Vision (C, F, R), Oxurion (C, R), Stealth BioTherapeutics (C, R), Carl Zeiss Meditec (F, R); R.P. Finger, Bayer (C), Ellex (C), Novartis (C, F), Chiese (C), Boehringer Ingelheim (C), Opthea (C), Alimera (C), Santhera (C), Roche/Genentech (C), CenterVue (F), Carl Zeiss Meditec (F), Biogen (F)